The reported EPS of $(1.78) indicates a loss per share, which could be viewed negatively by investors. However, the substantial cash position of $333.7 million provides a buffer and indicates financial stability. This mixed financial picture makes the short-term impact on the stock price uncertain, hence a neutral score. The high relevance is due to the direct mention of Sutro Biopharma's financial results. The importance is significant as EPS and cash position are key indicators of a company's financial health. The confidence level is high due to the clear financial figures provided.